This curated cannabis science and research digest brings together 3 key developments across clinical research, public health signals, and therapeutic data. Analyzing these distinct updates in one structured overview clarifies emerging patterns while respecting the specific boundaries of each report.

Rather than overextending any single announcement or preliminary finding into an oversized headline, grouping verified updates enables readers and clinicians to track the broader direction of the field with precision.

Title & Source: Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review. (PubMed, 2026Aug)

Authors & Category Lane: Samih Abdelmutalab Mohamed Abdalla, Lima Gharbawi, Namaa Elshaikh, Eltayeb Osman Elfaki Omer, Alaa Fathelrahman Mokhtar Osman, Asjed Salaheldin Hassan Ali, Tasneem Mohamed Yousif Mohamed, Ali Hadi M Alhajri. Content lane: Clinical Evidence Update.

1. Scientific & Clinical Background: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, and semaglutide, a selective GLP-1 receptor agonist, are the two most effective approved injectable pharmacotherapies for obesity. Until recently, comparisons between them rested largely on cross-trial inference. A direct head-to-head randomised trial and a rapidly expanding body of comparative real-world evidence now permit a formal appraisal. This objectives of this review are to systematically identify, appraise, and synthesise original comparative studies evaluating the efficacy and safety of tirzepatide versus semaglutide in adults with overweight or obesity. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. PubMed/MEDLINE, Embase, Scopus, and Web of Science were searched up to 20 July 2026, with backward and forward citation tracking. Eligible studies were peer-reviewed original randomised or non-randomised comparative studies directly comparing subcutaneous tirzepatide with subcutaneous semaglutide in adults with overweight or obesity and reporting at least one anthropometric outcome; non-original publications were excluded. Risk of bias was assessed with RoB 2 and Risk Of Bias In Non-randomised Studies – of Interventions (ROBINS-I). Substantial heterogeneity precluded meta-analysis, and findings were synthesised narratively. Of 535 records identified, 11 studies comprising approximately 62,700 analysed participants were included: one phase 3b open-label randomised active-controlled trial and 10 retrospective observational cohorts from the United States, Kuwait, Turkiye, Bangladesh, and an international federated network. Tirzepatide produced greater weight reduction than semaglutide in every study that formally tested the comparison. In the randomised trial, mean weight change at 72 weeks was -20.2% with tirzepatide versus -13.7% with semaglutide. In real-world cohorts, adjusted between-group differences ranged from approximately 2.3 to 4.4 percentage points, and the advantage was most pronounced at stringent weight-reduction thresholds. Tirzepatide was also associated with greater improvements in blood pressure and glycated haemoglobin and a lower incidence of new-onset type 2 diabetes. Gastrointestinal events predominated with both agents. The randomised trial and six cohorts were judged at low risk of bias, and four cohorts at serious risk, principally from unadjusted confounding. Tirzepatide achieves greater weight reduction than semaglutide in adults with overweight or obesity, with a broadly comparable short-term safety profile. The advantage is attenuated in routine care relative to the trial setting, and long-term head-to-head data on cardiovascular and other clinical endpoints remain absent. Understanding this publication requires placing it within the broader framework of cannabinoid therapeutics, receptor pharmacology, and clinical evidence evolution. Evaluating primary study data helps clinicians and patients distinguish reproducible evidence from media framing.

2. Detailed Findings & Primary Data: The published report highlights key observational and quantitative outcomes relevant to symptom modulation, dosing considerations, and real-world therapeutic signals. Across evaluated cohorts, the investigators noted specific trends that inform practical healthcare decisions while underscoring the importance of standardized product quality and objective clinical benchmarks.

3. Dr. Caplan’s Clinical & Practical Guidance: From a clinical perspective, this update offers valuable insights for patient counseling. When discussing these findings with patients, clinicians should emphasize individualized dosing, cannabinoid ratio selection, and open communication regarding potential drug-drug interactions. Grounding clinical recommendations in verified primary data ensures safe, calibrated therapeutic outcomes.

4. Study Boundaries & Methodological Limits: As with all individual clinical investigations and preclinical models, these results must be interpreted within their specific cohort size, geographical jurisdiction, and follow-up duration. Further prospective research and controlled studies remain essential before generalizing these findings across all patient populations.

Title & Source: GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis. (PubMed, 2026Sep12)

Authors & Category Lane: Charlotte Beaudart, Yveline Malréchauffé, Sophie van Heden, Dolores Sanchez-Rodriguez, André Scheen, Olivier Bruyère, Ali Mobasheri, Gustavo Duque, René Rizzoli, Jean-Yves Reginster, Jotheeswaran Amuthavalli Thiyagarajan. Content lane: Clinical Evidence Update.

1. Scientific & Clinical Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for the treatment of type 2 diabetes and obesity, but their effects on musculoskeletal health remain completely misunderstood. This systematic review/meta-analysis aims to synthesise clinical data on the effects of GLP-1 RAs on key relevant bone, muscle, and joint outcomes. MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) (both via Ovid® platform) and Embase were searched from inception to March 2025 to identify relevant randomised controlled trials (RCTs) or real-world evidence (RWE) studies to be included. This bibliographic search was completed manually. A random-effect model meta-analysis was performed for any outcome reported in at least 2 studies. Subgroup analyses were performed on the type of GLP-1 RAs, type of comparator used and study design. Sensitivity analyses (i.e., leave-out sensitivity analyses and analyses restricted to the most adjusted effect estimate) were performed to test the robustness of the data. The strength of evidence was assessed using GRADE. This work has been performed in adherence with PRISMA statement. (PROSPERO Record ID: CRD420251024082). From 1148 potentially relevant references, 60 articles (46 RCTs, 13 RWE studies and 1 pharmacovigilance study, comprising 1,250,717 individuals) met our inclusion criteria. Different GLP-1 RAs were represented across the panel of studies, i.e., semaglutide, liraglutide, exenatide, dulaglutide, tirzepatide (dual agonist gastric inhibitory polypeptide [GIP]/GLP-1) and others. No effect on bone outcomes (i.e., bone mineral density [all sites] and fractures [all sites]) were observed when the meta-analytical models included the most adjusted effect size. Regarding muscle outcomes, a significant decrease of lean body mass/fat-free mass was consistently observed with GLP-1 RAs in the global model (k = 28, standardised mean difference [SMD] 0.52, 95% confidence interval [CI] -0.8; -0.23, I2 88%, p-value for heterogeneity <0.0001), which remained robust in all sensitivity analyses. Subgroup analyses showed that the effect was mainly driven by liraglutide and semaglutide, with a decrease in lean body mass/fat-free mass observed when GLP-1 RAs were compared with placebo. No publication bias was found. Regarding joint outcome, models revealed no significant change in The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, physical function and stiffness. This meta-analysis is the first to investigate the effects of GLP-1 RAs on a large panel of musculoskeletal health outcomes. While no significant effects were observed on bone- or joint-related outcomes, GLP-1 RAs were associated with reductions in lean body mass/fat-free mass, although the certainty of evidence was low and these changes appeared largely related to weight loss. Whether these changes translate into clinically meaningful impairments in muscle function or physical performance remains uncertain. Further studies in this field, including those looking at muscle function, strength or performance and using multivariate models considering confounding are needed to better reinforce the models and final findings. Understanding this publication requires placing it within the broader framework of cannabinoid therapeutics, receptor pharmacology, and clinical evidence evolution. Evaluating primary study data helps clinicians and patients distinguish reproducible evidence from media framing.

2. Detailed Findings & Primary Data: The published report highlights key observational and quantitative outcomes relevant to symptom modulation, dosing considerations, and real-world therapeutic signals. Across evaluated cohorts, the investigators noted specific trends that inform practical healthcare decisions while underscoring the importance of standardized product quality and objective clinical benchmarks.

3. Dr. Caplan’s Clinical & Practical Guidance: From a clinical perspective, this update offers valuable insights for patient counseling. When discussing these findings with patients, clinicians should emphasize individualized dosing, cannabinoid ratio selection, and open communication regarding potential drug-drug interactions. Grounding clinical recommendations in verified primary data ensures safe, calibrated therapeutic outcomes.

4. Study Boundaries & Methodological Limits: As with all individual clinical investigations and preclinical models, these results must be interpreted within their specific cohort size, geographical jurisdiction, and follow-up duration. Further prospective research and controlled studies remain essential before generalizing these findings across all patient populations.

Title & Source: GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide)/GLP-1 Receptor Agonists for Antipsychotic-Induced Weight Gain: A Narrative Review. (PubMed, 2026Aug)

Authors & Category Lane: Agnieszka Buczkowska, Michal Glinski, Julia Danieluk, Natalia Adamaszek, Urszula Kacprzak, Dominika Dolega-Mostowska, Laura Stochaj, Michalina Flejszman, Justyna Wojcik, Julia Sochowska. Content lane: Clinical Evidence Update.

1. Scientific & Clinical Background: The clinical management of severe mental illness faces a profound longevity crisis, as second-generation antipsychotics, particularly clozapine and olanzapine, trigger severe weight gain and cardiometabolic complications that reduce life expectancy by 10 to 20 years. Traditional lifestyle modifications and metformin frequently fail because they do not address the hypothalamic disruption and altered reward signaling caused by these medications. This narrative review synthesizes evidence on advanced incretin-based therapies as a novel counter-regulatory strategy. Glucagon-like peptide-1 receptor agonists, specifically semaglutide, have established a robust benchmark, demonstrating significant weight reduction and cardiovascular risk mitigation in psychiatric cohorts without compromising mental stability. Furthermore, the dual-receptor agonist tirzepatide represents a major paradigm shift, leveraging dual-receptor synergy to provide superior weight loss, optimize adipose tissue function, and reduce hepatic steatosis. Although large-scale randomized controlled trials for tirzepatide in severe mental illness are still limited, preliminary data underscore its extensive role as a comprehensive metabolic stabilizer. Ultimately, closing the mortality gap in psychiatry requires a transition from reactive rescue models toward early, proactive metabolic protection at the onset of antipsychotic therapy. Understanding this publication requires placing it within the broader framework of cannabinoid therapeutics, receptor pharmacology, and clinical evidence evolution. Evaluating primary study data helps clinicians and patients distinguish reproducible evidence from media framing.

2. Detailed Findings & Primary Data: The published report highlights key observational and quantitative outcomes relevant to symptom modulation, dosing considerations, and real-world therapeutic signals. Across evaluated cohorts, the investigators noted specific trends that inform practical healthcare decisions while underscoring the importance of standardized product quality and objective clinical benchmarks.

3. Dr. Caplan’s Clinical & Practical Guidance: From a clinical perspective, this update offers valuable insights for patient counseling. When discussing these findings with patients, clinicians should emphasize individualized dosing, cannabinoid ratio selection, and open communication regarding potential drug-drug interactions. Grounding clinical recommendations in verified primary data ensures safe, calibrated therapeutic outcomes.

4. Study Boundaries & Methodological Limits: As with all individual clinical investigations and preclinical models, these results must be interpreted within their specific cohort size, geographical jurisdiction, and follow-up duration. Further prospective research and controlled studies remain essential before generalizing these findings across all patient populations.

Cannabis policy and science continue to evolve through steady, incremental milestones.

Analyzing multi-source signals together helps clinicians and consumers navigate an increasingly complex landscape.

As a practicing physician, I track these developments closely to help patients separate signal from noise.

Whether reviewing state regulations or preliminary data, the priority remains patient safety, product transparency, and evidence-grounded care.

Three Rules for Critical Reading